BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 12827399)

  • 1. [Treatment of psoriatic arthritis with TNF alpha-antagonists].
    Antoni C; Manger B
    Z Rheumatol; 2003 Jun; 62(3):235-9. PubMed ID: 12827399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etanercept: new indication. For ankylosing spondylitis: another option.
    Prescrire Int; 2005 Jun; 14(77):92-3. PubMed ID: 15981387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
    Tobin AM; Kirby B
    BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.
    Delaunay C; Farrenq V; Marini-Portugal A; Cohen JD; Chevalier X; Claudepierre P
    J Rheumatol; 2005 Nov; 32(11):2183-5. PubMed ID: 16265699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of psoriatic arthritis therapies.
    Gladman DD
    Semin Arthritis Rheum; 2003 Aug; 33(1):29-37. PubMed ID: 12920694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis.
    Krueger G; Callis K
    Arch Dermatol; 2004 Feb; 140(2):218-25. PubMed ID: 14967799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis.
    Stokes DG; Kremer JM
    Semin Arthritis Rheum; 2003 Aug; 33(1):1-18. PubMed ID: 12920692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arthralgia as an adverse event to infliximab: a reactive arthritis or triggering of psoriatic arthritis? Successful management by switching to etanercept.
    Moustou AE; Stratigos AJ; Vergou T; Gregoriou S; Georgala S; Danopoulou I
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):968-9. PubMed ID: 19207660
    [No Abstract]   [Full Text] [Related]  

  • 9. Guideline for anti-TNF-alpha therapy in psoriatic arthritis.
    Kyle S; Chandler D; Griffiths CE; Helliwell P; Lewis J; McInnes I; Oliver S; Symmons D; McHugh N;
    Rheumatology (Oxford); 2005 Mar; 44(3):390-7. PubMed ID: 15695305
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
    Tijhuis GJ; van de Putte LB; Breedveld FC
    Ned Tijdschr Geneeskd; 2001 Sep; 145(39):1880-5. PubMed ID: 11605312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
    Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
    Bansback NJ; Ara R; Barkham N; Brennan A; Fraser AD; Conway P; Reynolds A; Emery P
    Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriatic arthritis patients doing better on infliximab than etanercept.
    Smith N; Gadsby K; Deighton C
    Rheumatology (Oxford); 2007 Apr; 46(4):721-2. PubMed ID: 17314216
    [No Abstract]   [Full Text] [Related]  

  • 14. TNFalpha therapy in psoriatic arthritis and psoriasis.
    Mease P
    Ann Rheum Dis; 2004 Jul; 63(7):755-8. PubMed ID: 15194567
    [No Abstract]   [Full Text] [Related]  

  • 15. Etanercept: an evolving role in psoriasis and psoriatic arthritis.
    Prodanovich S; Ricotti C; Glick BP; Inverardi L; Leonardi CL; Kerdel F
    Am J Clin Dermatol; 2010; 11 Suppl 1():3-9. PubMed ID: 20586498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
    Jonsdottir T; Forslid J; van Vollenhoven A; Harju A; Brannemark S; Klareskog L; van Vollenhoven RF
    Ann Rheum Dis; 2004 Sep; 63(9):1075-8. PubMed ID: 15066863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis.
    Mease PJ
    Skin Therapy Lett; 2003 Jan; 8(1):1-4. PubMed ID: 12728284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating psoriatic arthritis: how effective are TNF antagonists?
    Gottlieb AB; Antoni CE
    Arthritis Res Ther; 2004; 6 Suppl 2(Suppl 2):S31-5. PubMed ID: 15228619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follow-up of psoriatic arthritis mutilans patients treated with anti-TNF-alpha therapy.
    Pomerantz RG; Mody E; Husni ME; Qureshi AA
    J Drugs Dermatol; 2009 Apr; 8(4):406-12. PubMed ID: 19363860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.
    Buch MH; Seto Y; Bingham SJ; Bejarano V; Bryer D; White J; Emery P
    Arthritis Rheum; 2005 Jan; 52(1):42-8. PubMed ID: 15641046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.